Rishi Kumar V^1*, Senthil Kumar Shakthivel²

¹Assistant Professor, ²Associate Professor, Department of General Medicine, Shri Sathya Sai Medical College and Research Institute, INDIA.

Email: rishimddoc@rocketmail.com

REFERENCES

1. Reddy KS. Cardiovascular disease in non-Western countries. N Engl J Med. 2004;350(24):2438–2440.
2. R. Gupta, P. Joshi, V. Mohan, K.S. Reddy, S. Yusuf, Epidemiology and causation of coronary heart disease and stroke in India Heart, 94 (2008), pp. 16-26
3. Woodard GE, Rosado JA. Recent advances in natriuretic peptide research. J Cell Mol Med. 2007;11(6):1263-1271.
4. Peacock WF, 4th, Fonarow GC, Emerman CL, Mills RM, Wynne J. ADHERE Scientific Advisory Committee and Investigators; Adhere Study Group. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology. 2007;107:44–51.
5. Wiley CL, Switzer SP, Berg RL, Glurich I, Dart RA. Association of B-type natriuretic Peptide levels with estimated glomerular filtration rate and congestive heart failure. Clin Med Res. 2010;8(1):7-12.
6. Seino, Y., Ogawa, A., Yamashita, T., Fukushima, M., Ogata, K.-i., Fukumoto, H. and Takano, T. (2004), Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. European Journal of Heart Failure, 6: 295-300.
7. Bay M, Kirk V, Parner J, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart. 2003;89(2):150-154.
8. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb;27(3):330-7.
9. Tsao CW, Lyass A, Larson MG, et al. Prognosis of Adults With Borderline Left Ventricular Ejection Fraction. JACC Heart Fail. 2016;4(6):502-510.
10. Gaggin HK, Truong QA, Rehman SU, et al. Characterization and prediction of natriuretic peptide “nonresponse” during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail. 2013;19:135–42.
11. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillière Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007 Apr 24;49(16):1733-9.
12. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 2010 Feb 16;55(7):645-53.
13. Kaufmann BA, Goetschalckx K, Min SY, Maeder MT, Bucher U, Nietlispach F, Bernheim AM, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF investigators. Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy. Int J Cardiol. 2015 Jul 15;191:286-93.
14. Ozturk TC, Unluer E, Denizbasi A, Guneysel O, Onur O. Can NT-proBNP be used as a criterion for heart failure hospitalization in emergency room?. J Res Med Sci. 2011;16(12):1564-1571.